Beta Bionics Receives FDA Clearance For Its Mint Pump That Requires No Recharging And Integrates With Industry-Leading Continuous Glucose Monitors; Lowers FY26 Sales Guidance From $131M-$136M To $121M-$126M Reflecting Potential Revenue Deferral Impact Of Up To $10M In Q4 As New Prospective iLet Users Could Choose To Await The Launch Of Mint
Mint enables smartphone control for iOS and Android users. Mint is expected to meaningfully expand the Company’s addressable insulin delivery market, particularly among people with diabetes seeking a patch pump form
Beta Bionics got approval for a new pump called Mint that doesn't need recharging. Some customers are waiting to buy Mint instead of buying now, so the company lowered its sales forecast for 2026.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.